With more than two decades of experience at
Genzyme and GSK and his recent leadership of Dutch to-BBB as CEO,
Mr. van Weperen brings significant business operational and
commercial expertise to Prosensa in advance of an anticipated
launch of the company's first product for the treatment of Duchenne
muscular dystrophy (DMD).
Hans Schikan, CEO of Prosensa said, "We expect
Willem to play a critical role at Prosensa as we move from a
research and development stage company to a commercial
organization. His knowledge and experience will be invaluable as we
build the infrastructure to support the anticipated launch of our
first product for treating boys with DMD."
Prior to his role at to-BBB, Mr. van Weperen
spent 15 years at Genzyme in a number of senior management and
commercial positions at both a national and international level. He
joined Genzyme in 1994 as medical affairs manager in
"I'm thrilled to be joining Prosensa at such an
exciting and pivotal time for the company and look forward to
applying my expertise in commercializing rare disease drugs to
potentially launching one of the first products to treat DMD," said
Mr. van Weperen.
Dr. Jenkins joins Prosensa's Supervisory Board
with more than 25 years of experience in the healthcare sector. In
her most recent role as Head of
"We are delighted to welcome Annalisa to
Prosensa's Supervisory Board. Her extensive experience in research
and clinical development and medical affairs for Merck Serono and
Bristol Myers Squibb, which are amongst the top pharma
companies in the world, will bring valuable insights to us as we
take the company to the next level," said
Dr. Jenkins began her career as a Medical
Officer with the
"I am excited to join Prosensa at such a significant moment in the company's history and look forward to working alongside a world-class team with exceptional leadership in rare diseases," said Dr. Jenkins. "With such an extensive research and development pipeline in DMD, I hope to integrate my expertise in global R&D as Prosensa continues to advance its portfolio of innovative exon-skipping technology."
The appointment of Dr.
Notes to editors
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), myotonic dystrophy and
Prosensa's current portfolio includes six compounds for the treatment of DMD, all of which have received orphan drug status in
Celia EconomidesProsensa Holding N.V. Sr Director IR & Corporate Communications email@example.com
Source: Prosensa Holding N.V.